PYXS Stock Analysis
PY
Uncovered
Pyxis Oncology Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 73 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. The firm leverages its fully integrated research, development, and commercial capabilities to build a diversified portfolio of next-generation therapeutics. The firm's therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The firm has developed a broad portfolio of novel antibody-drug conjugate (ADC), immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. The firm's product pipelines are PYX-201 and PYX-106.